Medtronic MIS corrective actions bring firm back in compliance with GMPs -- FDA "close-out" letter.
This article was originally published in The Gray Sheet
Executive SummaryMEDTRONIC MICRO INTERVENTIONAL SYSTEMS' GMP PROCEDURES get a clean bill of health from FDA in a warning letter "close-out" correspondence sent to the company in late November, the firm says. FDA said in the letter that Medtronic MIS has corrected good manufacturing deficiencies identified by FDA in an Oct. 24 warning letter, including customer complaint handling, package seal inspection parameters and provisions for the reworking of defective packaging.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.